Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 9/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792990 | 0.90 | SUV39H2 (0.41) | SUV39H2DRD2DYRK1ABRD4PDPK1 | |
| SCHEMBL6793931 | 0.86 | DYRK1A (0.50) | DRD2DYRK1ABRD4 | |
| SCHEMBL6793960 | 0.83 | BRD4 (0.38) | DRD2DYRK1ABRD4PDPK1CCNB2 | |
| SCHEMBL6787521 | 0.78 | AKR1C3 (0.38) | DRD2BRD4 | |
| SCHEMBL6791673 | 0.77 | DYRK1A (0.51) | DRD2DYRK1ABRD4 | |
| SCHEMBL6792474 | 0.76 | BRD4 (0.38) | DRD2DYRK1ABRD4PDPK1CCNB2 | |
| SCHEMBL6791824 | 0.75 | DRD2 (0.41) | SUV39H2DRD2DYRK1ABRD4PDPK1 | |
| SCHEMBL31357648 | 0.72 | BCHE (0.46) | DRD2BRD4 | |
| SCHEMBL6788076 | 0.71 | AKR1C3 (0.37) | SUV39H2DRD2BRD4 | |
| SCHEMBL6791840 | 0.70 | DYRK1A (0.51) | DRD2DYRK1ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | SUV39H2 3165/4885DRD2 4396/4885DYRK1A 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.